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OBJECTIVE: Infections of snake bite wounds by Shewanella are rarely discussed in the medical literature. This study
aims to characterize the presentation and management of Shewanella infections in snake bite wounds.
METHOD: We retrospectively investigated the microbiology, clinical features, and outcomes of patients with
Shewanella infected snake bite wounds admitted to a tertiary medical center from January 1998 to December 2009.
RESULTS: Ten patients with Shewanella-infected snake bite wounds were identified. All of the snake bites were
caused by cobras. The majority of patients had moderate to severe local envenomation and polymicrobial
infections. Shewanella isolates are susceptible to ampicillin-sulbactam, piperacillin-tazobactam, third- and fourth-
generation cephalosporins, carbapenems, aminoglycosides, and quinolones but are resistant to penicillin and
cefazolin. All of the patients examined had favorable outcomes.
CONCLUSION: It is recommended that Shewanella infection be considered in snake bite patients, especially when
patients present with moderate to severe local envenomation.
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INTRODUCTION
Snake bite envenomation is a common medical emer-
gency in the tropics (1). An estimated 421,000 envenomings
result from snake bites each year worldwide and that these
envenomings cause 20,000 deaths annually (2). Moreover,
many patients suffer permanent disabilities from wound
complications (3-5). Bacterial wound infection is a major
cause of wound complications. As many as 30.8% of snake
bite victims suffer wound infections (6). While serious
systemic illnesses occur infrequently as a result of these
infections, they can lead to sepsis and death (7,8).
Various organisms have been reported to cause infections
after snake bites. Polymicrobial infections are seen fre-
quently, with Enterobacteriaceae being among the most
common isolates (9). A recent study of snake bite wound
infection reported the isolation of species in the Shewanella
genus from 3 patients; however, the species of snake
involved and patient details were not provided (10).
Shewanella is a non-fermentative Gram-negative bacteria
that occurs worldwide (11). In a surveillance study of snake
oral bacteria in Hong Kong, Shewanella was present in the
oropharynx of the Chinese cobra (Naja atra) (12).
Few studies have reported on Shewanella infections; those
that have consist mostly of isolated case reports and case
series (13). Soft tissue infection is the most commonly
described presentation in human infections (14). There is
little published data on Shewanella infections in association
with snake bites.
Shewanella is probably an underestimated and under-
reported cause of wound infections following snake bite.
We therefore sought to determine the clinical features of
Shewanella infection through a retrospective review of the
microbiology records of patients with snake bites seen over a
12-year period.
MATERIALS AND METHODS
The medical records of patients with Shewanella-infected
snake bite wounds who presented to the Taichung Veterans
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General Hospital, a tertiary medical center in Taiwan,
between January 1998 and December 2009 were reviewed.
Patients were identified using the institution’s electronic
database. Clinical, laboratory, and microbiology data were
retrieved from the patients’ medical records. Two indepen-
dent researchers reviewed and confirmed the medical
records.
The identification of the snake species involved in each
case was based on: 1) inspection of the snake if it had been
brought to the hospital; or 2) the patient’s identification of
the snake using a venomous snake chart and the corre-
sponding clinical manifestations.
The effects of the snake bite on the surrounding tissue
were classified into three categories of clinical severity as
defined in previous studies: 1) minimal– swelling,
erythema, or ecchymosis confined to the site of the bite, 2)
moderate– progression of swelling, erythema, or ecchymo-
sis beyond the site of the bite, or 3) severe- rapid swelling,
erythema, or ecchymosis involving the entire limb. This
classification is in accord with the severity classification
system proposed by Gold et al. (15).
The method for sampling wound tissue was adopted
from previous studies (16,17). A deep tissue culture
obtained by biopsy during the initial debridement was
performed. Specimens obtained from the open necrotic area,
the draining of abscesses and hematomas were not included
because of possible contamination.
The identification of Shewanella was based on Gram
staining, colony morphology, and biochemical characteristics.
Antibiotic susceptibility testing was performed using a disk-
diffusion technique involving the use of Oxoid disks
according to the Clinical and Laboratory Standards Institute
guidelines.
The study protocol was approved by the Institutional
Review Board of the Taichung Veterans General Hospital.
(C10257).
RESULTS
Ten patients were identified as having a snake bite wound
infected with Shewanella. Each patient had been bitten by
a cobra, one of six medically important venomous snakes
in Taiwan; other venomous snakes in Taiwan include
Trimeresurus mucrosquamatus, Trimeresurus stejnegeri, Bun-
garus multicinctus, Deinagkistrodon acutus, and Daboia russelii
siamensis (18).
All of the patients presented with local symptoms typical
of cobra bites. Pain, erythema and swelling were noted in all
cases, as well as characteristic dark discoloration around the
fang mark. Nine of the patients had necrotic wounds at the
time of presentation. The local reaction to envenomation
was rated moderate to severe in nine of the patients
(Table 1). Four patients, who had been bitten in the upper
portion of their limb, developed compartment syndrome.
None of these patients developed symptoms of systemic
poisoning, such as changes in consciousness, paralysis, or
paresis. The median age of the patients was 42.5 years
(range, 26-88 years). Two of the patients had hypertension,
Table 1 - Clinical characteristics of 10 patients with a Shewanella infected wound from a cobra bite.
Case
no.
Age in
years,
Sex
Underlying
condition
Month of
presentation
Site of
the
bite
Delay
between
bite and
treatment
(hours)
Symptoms at
presentation
Local severity of
envenomation
Compartment
syndrome
Other organisms
isolated
Antibiotic
therapy
1 39, M April Left
hand
18 P, E, S, B, N Severe Yes Morganella
morganii,
Providencia
rettgeri,
Enterococcus
ciprofloxacin
2 88, F Hypertension July Left
foot
32 P, E, S Moderate No Morganella
morganii
ceftriaxone
3 48, F August Left
foot
16.5 P, E, S, B, N Severe No Morganella
morganii,
Bacteroides
fragilis,
Enterococcus
ampicillin/
sulbactam
4 63, M Hypertension August Right
hand
23 P, E, S, N Severe Yes Aeromonas
hydrophila,
Enterococcus
ampicillin/
sulbactam
5 38, M July Right
hand
2.5 P, E, S, N Severe Yes ampicillin/
sulbactam
6 46, M May Left
hand
4 P, E, S, N Moderate Yes Morganella
morganii
ceftriaxone
7 38, F June Right
foot
2 P, E, S, N Moderate No Bacteroides
fragilis,
Providencia
stuartii
ceftazidime,
metronidazole
8 29, F October Left
foot
1 P, E, S, N Moderate No Providencia
rettgeri
ampicillin/
sulbactam
9 72, F October Right
foot
5 P, E, S, B, N Moderate No Proteus vulgaris cefoxitin
10 26. F July Right
foot
4 P, E, S, B, N Mild No amoxicillin/
clavulanate acid
P, pain; S, swelling; E, erythema; B, bullous; N: necrosis.
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but the other eight patients had no underlying disease. All
of the cases occurred between April and October. Six of the
patients were bitten while working on farms. The bites were
localized to the lower limbs in six of the patients; the bites in
the remaining patients were localized in the upper limbs.
The mean time that elapsed after the bite and prior to arrival
at the hospital was 10.8 hours (range 1-32 hours).
Two patients had monomicrobial infections, while eight
had concomitant polymicrobial infections. The concomitant
pathogens isolated included: Morganella morganii (four
patients), Providencia species (three patients), Enterococcus
species (three patients), Bacteroides fragilis (two patients),
and Aeromonas hydrophila (one patient) and Proteus vulgaris
(one patient).
All of the patients received anti-venom treatment and
underwent wound debridement. With regard to antimicro-
bial treatment, most of the patients received broad-spectrum
beta-lactam antibiotics, including ampicillin/sulbactam
(four patients), ceftriaxone (two patients), amoxicillin-
clavulanate (one patient), ceftazidime (one patient), and
cefoxitin (one patient). One patient received ciprofloxacin.
The majority of patients experienced prolonged hospitaliza-
tion with an average stay in the hospital of 23.5 days. All of
the infections were treated successfully.
All of the Shewanella isolates tested were susceptible to
ampicillin-sulbactam, piperacillin-tazobactam, third- and
fourth-generation cephalosporins, carbapenems, aminogly-
cosides, and quinolones (Table 2). Ninety percent of the
isolates tested were susceptible to trimethoprim-sulfa-
methoxazole and chloramphenicol, while 83% were suscep-
tible to ampicillin. All of the Shewanella isolates tested were
resistant to penicillin and cefazolin.
DISCUSSION
This study reports 10 cases of Shewanella infection in
wounds resulting from cobra bites. Among them, nine had
moderate to severe local envenomation, and four patients in
this group experienced compartment syndrome. Shewanella
isolates in the study were characteristically susceptible to
most third- and fourth-generation cephalosporins and
piperacillin but resistant to penicillin and cefazolin.
Cobra bite is a major cause of morbidity and mortality in
Asia (19). Furthermore, wound infection is a common and
severe complication of cobra bite (10). In a retrospective
study performed over a 10-year period, Chen et al. reported
that cobra bites cause more wound infections than any other
type of venomous snake and result in more severe
complications (10). Death due to necrotizing fasciitis after
a cobra bite has been reported (8). Our results suggest that
the patients who had Shewanella-infected wounds were
likely to have been bitten by a cobra. The frequent
occurrence of complications from infection at the site of a
cobra bite is the result of the synergistic effects of
envenomation and contamination with pathogenic bacteria.
Cobra venom contains cytotoxins, which are responsible for
the swelling and tissue necrosis that spread rapidly after
envenomation (20). When humans are envenomated, the
cytotoxins released induce enzymatic destruction of the
endothelium and connective tissue, which results in
necrosis at the site of the bite and produces an ideal
environment for bacterial proliferation. Upon envenoma-
tion, a potent inoculum of bacteria is introduced by the
snake’s fangs. Previous studies have shown that wound
infections develop more frequently in moderate to severe
snake bite wounds (21), like those experienced by the
majority (9/10) of our patients.
Cobra venoms are neurotoxic, hemotoxic and cardiotoxic
(22). However, local necrosis is the most prominent clinical
feature of cobra bites in many parts of Asia; neurotoxic
manifestations are uncommon (20,23). Our findings are in
agreement with previous observations, as none of our
patients had neurological symptoms or signs. Another
study of cobra bites in Sri Lanka found that local symptoms
were the only manifestation in most cases (4). The varied
presentation of patients after cobra envenomation may
reflect geographical variation in the composition of cobra
venom (24). The mainstay of treatment for cobra envenoma-
tion is the administration of anti-venom (25). However,
published studies have failed to demonstrate that anti-
venom administration has a significant effect in controlling
local tissue necrosis and its sequelae at the site of the bite
(4,20).
Four of the cobra-bitten patients in our study developed
compartment syndrome. These patients were all bitten on
the upper limbs. Shewanella was unlikely the sole cause of
the compartment syndrome. Morganella morganii, Aeromonas
hydrophila, Providencia rettgeri, and Enterococcus were also
isolated from these patients and may have contributed to
the compartment syndrome. The venom-induced tissue
destruction may have prompted the development of
compartment syndrome, leaving the wound susceptible to
Shewanella infection (23).
The source of the bacteria found in these wound
infections may be bacteria inhabiting the snake’s oral cavity
(26-28). In a survey of snake oral bacterial flora in Hong
Kong, cobras harbored many types of bacteria, including
enteric and coliform organisms (12,29). Shewanella has been
found within the oral cavities of Chinese cobra specimens
(12). Thus, these animals are a likely source of the bacteria
that caused the wound infections in our patients. The
affinity of Shewanella for necrotic tissue has been reported
(30-32). Necrosis is an important feature of cobra bites and
provides an ideal environment for the growth of Shewanella.
Our data also support previous observations that poly-
microbial infections are common both in infected snake bite
wounds (9) and Shewanella infections (33). Because
Shewanella infections are uncommon and because these
Table 2 - Antimicrobial susceptibility data for the
Shewanellla isolates.
Antimicrobial agent No. of susceptibility isolates (%)
Ampicillin-sulbactam 10/10 (100)
Piperacillin-tazobactam 10/10 (100)
Cefotaxime 6/6 (100)
Ceftazidime 10/10 (100)
Cefepime 9/9 (100)
Imipenem 7/7 (100)
Aztreonam 6/6 (100)
Amikacin 10/10 (100)
Gentamicin 10/10 (100)
Minocycline 6/6 (100)
Ciprofloxacin 8/8 (100)
Trimethoprim-sulfamethoxazole 9/10 (90)
Chloramphenicol 9/10 (90)
Ampicillin 5/6 (83)
Cefazolin 0/6 (0)
Penicillin 0/8 (0)
CLINICS 2012;67(5):431-435 Shewanella infection after snake bite
Liu PY et al.
433
bacteria are often isolated with other organisms, the clinical
significance of these infections has been obscured. More
recently, increased numbers of monomicrobial Shewanella
infections have been reported, and this type of infection
may contribute to a more fulminant clinical course.
Moreover, animal studies have confirmed the pathogenicity
of Shewanella (34). Shewanella algae and Shewanella putrefa-
ciens are the only two species of the genus known to cause
human infections (14). Shewanella is often a component of a
polymicrobial infection. The most common clinical syn-
drome caused by Shewanella is an infection of the skin and
soft tissue (35). Hepatobiliary diseases and malignancy are
the most common underlying diseases in cases of Shewanella
infection, which is in contrast to the patients described in
this study, most of whom (8/10) were in good health before
the injury. The overall mortality rate for Shewanella infec-
tions can be as high as 20 to 30%; this high mortality may be
due to severe underlying disease in many cases (13). All of
the patients reported in our study that presented with acute
Shewanella wound infections survived to discharge. This
result was due in part to early diagnosis, which made
prompt treatment possible. The lack of any underlying
disease is another possible cause of the favorable outcomes
in our patients.
As with other cases of bacterial wound infection,
definitive treatment should be based on antimicrobial
susceptibilities and involve adequate surgical debridement.
Antimicrobial susceptibility data for our isolates and our
clinical results are consistent with those described by other
investigators. Specifically, Shewanella is characteristically
susceptible to ampicillin-sulbactam, piperacillin-tazobac-
tam, third- and fourth-generation cephalosporins, carbape-
nems, aminoglycosides and quinolones but resistant to
penicillin and cefazolin (13,36). These data suggest that
initial therapy for Shewanella infection could include a
broad-spectrum beta-lactam antibiotic or a fluoroquinolone.
Broad-spectrum beta-lactam antibiotics and fluoroquino-
lones are also effective against other common pathogens
associated with snake bites. Ninety percent of isolates were
susceptible to chloramphenicol, which is often used in the
treatment of infected wounds from snake bites (37).
However, penicillin and cefazolin, which are often recom-
mended for the empiric treatment of infected wounds from
venomous snakes other than cobras (16,38), have poor
activity against Shewanella. In our opinion, physicians
should consider the species of venomous snake involved
when selecting an appropriate antibiotic.
Although Shewanella is susceptible to many antibiotics,
the existence of carbapenem-resistant strains has been
reported (33). Furthermore, Lascols et al. have reported
that a chromosomally encoded gene, qnr3, may confer
resistance to fluoroquinolones in Shewanella (39). The
emergence of resistance to piperacillin-tazobactam (40)
and imipenem (41) during treatment has been reported.
The failure of treatment should alert the clinician to the
possibility of emerging resistance.
One limitation of our study is that it reported detailed
information from only one tertiary care center. In that
sense, our data set does not represent a general patient
population and is subject to biases regarding referrals for
advanced care. Patients with mild cases are probably
underrepresented.
Second, we did not identify the isolated Shewanella
samples at the species level. Because S. algae is not included
in the databases used by many of the automated identifica-
tion systems, many clinical microbiology laboratories
identify both species as S. putrefaciens (34). Thus, a number
of the infections reported as S. putrefaciens may actually
correspond to S. algae infections. Furthermore, only mole-
cular characterization can definitively distinguish S. putre-
faciens and S. algae from other species of the Shewanella
genus (35).
Third, snake species identification was not confirmed by
herpetologists due to the nature of a retrospective study.
The identification of a snake species by doctors, victims, and
witnesses can be unreliable (42). Immunodiagnostic meth-
ods for snake identification have been proposed (1). Some
experts advocate another approach; the use of diagnostic
algorithms based on a previously established snake bite
database (42).
In conclusion, this study provides further evidence that
Shewanella is a pathogen associated with snake bite wound
infections, especially in patients with moderate to severe
local envenomation. The use of broad-spectrum beta-lactam
antibiotics and debridement are associated with good
outcomes. Several issues require further study. The entire
spectrum of wound infections after snake bite requires close
investigation. This topic may be best investigated by
prospective integral observation studies. A comprehensive
survey of the bacterial oral flora found in venomous snakes
in this region is urgently needed.
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